Enovis (NYSE:ENOV) Hits New 12-Month Low – Time to Sell?

Enovis Corporation (NYSE:ENOV) hit a new 52-week low on Thursday. The company traded as low as $17.16 and last traded at $17.19, with a volume of 170,330 shares. The stock had previously closed at $17.61.

Analysts Set New Price Targets

Several analysts have weighed in on ENOV shares. BTIG Research lowered their price target on Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a report on Tuesday, September 1st. Wall Street Zen lowered Enovis from a “buy” rating to a “hold” rating in a report on Saturday. Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Citizens Jmp lowered their target price on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a research note on Wednesday, September 2nd. Finally, Canaccord Genuity Group dropped their target price on shares of Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, August 17th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Enovis presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

Enovis Stock Up 1.7%

The stock has a 50-day simple moving average of $21.74 and a two-hundred day simple moving average of $23.29. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. The firm has a market cap of $1.02 billion, a PE ratio of -0.92 and a beta of 1.37.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. The firm had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts expect that Enovis Corporation will post 3.15 earnings per share for the current year.

Insider Activity at Enovis

In other Enovis news, insider Oliver Engert purchased 2,660 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were purchased at an average cost of $18.80 per share, with a total value of $50,008.00. Following the completion of the purchase, the insider owned 63,898 shares of the company’s stock, valued at $1,201,282.40. The trade was a 4.34% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Damien Mcdonald acquired 13,035 shares of the stock in a transaction dated Friday, September 4th. The stock was acquired at an average price of $19.15 per share, with a total value of $249,620.25. Following the completion of the acquisition, the chief executive officer owned 247,077 shares in the company, valued at approximately $4,731,524.55. The trade was a 5.57% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders acquired 23,293 shares of company stock valued at $449,599. 2.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Enovis

Several institutional investors and hedge funds have recently made changes to their positions in ENOV. Paradigm Capital Management Inc. NY bought a new position in Enovis during the 2nd quarter worth approximately $28,533,000. Bank of America Corp DE purchased a new position in Enovis in the 2nd quarter worth approximately $11,502,000. Man Group plc bought a new stake in Enovis in the second quarter valued at approximately $8,711,000. Front Street Capital Management Inc. lifted its position in Enovis by 106.1% in the first quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after purchasing an additional 384,124 shares during the last quarter. Finally, Private Management Group Inc. lifted its position in Enovis by 38.8% in the second quarter. Private Management Group Inc. now owns 1,365,082 shares of the company’s stock valued at $28,257,000 after purchasing an additional 381,705 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient outcomes and support the restoration of movement. Its portfolio serves orthopedic, rehabilitation and recovery markets, with products used by physicians, hospitals, physical therapists, athletic trainers and consumers.

The company’s offerings include orthopedic braces and supports, cold and compression therapy systems, rehabilitation equipment, electrical stimulation and ultrasound products, surgical implants and related technologies.